Risk of new‐onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen‐deprivation therapy for prostate cancer
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the incidence of new‐onset diabetes mellitus (NODM) and of worsening glycaemic control in established DM after starting androgen‐deprivation therapy (ADT) for prostate cancer, as ADT is associated with altered body composition, potentially influencing insulin sensitivity. PATIENTS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between January 1989 and July 2005; those with incomplete information and those receiving only neoadjuvant ADT were excluded. Variables examined included age, race, body mass index (BMI), pretreatment prostate‐specific antigen, Gleason sum, clinical stage, ADT type (medical vs surgical) and schedule (continuous vs intermittent), presence of pre‐existing DM, serum glucose and glycosylated haemoglobin (HbA1c) levels before and after ADT, and receipt of vitamin D or bisphosphonate supplementation. Data were analysed statistically and P < 0.05 considered to indicate significance. RESULTS: In all, 396 patients (median age 73.2 years; median BMI of 26.7 kg/m 2 at ADT initiation) were analysed. Of these, 59.1% were African‐American and 40.9% were Caucasian/other. At a median follow‐up of 60.1 months, 36 (11.3%) patients developed NODM. In 77 patients with pre‐existing DM, there was an increase of ≥10% in serum HbA1c or fasting glucose levels in 15 (19.5%) and 22 (28.6%), respectively. On multivariate analysis, a BMI of ≥30 kg/m 2 was associated with an increased risk of developing NODM (odds ratio 4.65, P = 0.031). Receipt of vitamin D had a protective effect (odds ratio 5.75, P = 0.017). CONCLUSIONS: Patients receiving ADT for prostate cancer with or with no history of DM should have routine surveillance of glycaemic control, particularly when their BMI is ≥ 30 kg/m 2 , with appropriate preventive and treatment measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Insulin sensitivity during combined androgen blockade for prostate cancer
Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493
The Current State of Hormonal Therapy for Prostate Cancer
Hellerstedt, B. A., & Pienta, K. J. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.3.154 · Cited by 386
Haffner, S. M., Valdez, R. A., Mykkänen, L., Stern, M. P., & Katz, M. S. (1994) · Metabolism · doi:10.1016/0026-0495(94)90202-x · Cited by 226
Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study
Simon, D., Preziosi, P., Barrett-Connor, E., Roger, M., Saint-Paul, M., Nahoul, K., & Papoz, L. (1992) · Diabetologia · doi:10.1007/bf00402551 · Cited by 157
Cited by
Obesity and Prostate Cancer: Weighing the Evidence
Allott, E. H., Masko, E. M., & Freedland, S. J. (2013) · European Urology · doi:10.1016/j.eururo.2012.11.013 · Cited by 601
Testosterone: a metabolic hormone in health and disease
Kelly, D. M., & Jones, T. H. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0455 · Cited by 577
Sadovsky, R., Basson, R., Krychman, M., Morales, A. M., Schover, L., Wang, R., & Incrocci, L. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01620.x · Cited by 310
The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance
Traish, A. M., Saad, F., & Guay, A. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.005751 · Cited by 266
Short-Term Estrogen Withdrawal Increases Adiposity in Healthy Men
Chao, J., Rubinow, K. B., Kratz, M., Amory, J. K., Matsumoto, A. M., & Page, S. T. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1482 · Cited by 25
Metadata
- Authors
- Derweesh, I. H., DiBlasio, C. J., Kincade, M. C., Malcolm, J. B., Lamar, K. D., Patterson, A. L., Kitabchi, A. E., & Wake, R. W.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2007-09-14
- Volume
- 100
- Issue
- 5
- Pages
- 1060-1065
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W2138638265
- Cited by
- 104
- References
- 9
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of new‐onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen‐deprivation therapy for prostate cancer. https://app.cochat.ai/papers/10.1111/j.1464-410x.2007.07184.x
- The paper
- Derweesh, I. H., DiBlasio, C. J., Kincade, M. C., Malcolm, J. B., Lamar, K. D., Patterson, A. L., Kitabchi, A. E., & Wake, R. W. (2007). Risk of new‐onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen‐deprivation therapy for prostate cancer. BJU International. https://doi.org/10.1111/j.1464-410x.2007.07184.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.